As you have seen, it has been a very active time at Eton. During the call, we will review fourth quarter results, provide ...
Q4 2025 Earnings Call March 19, 2026 4:30 PM EDTCompany ParticipantsDavid Krempa - Chief Business OfficerSean Brynjelsen ...
bSt George's University Hospitals NHS Foundation Trust, London, UK cKing's College Hospital NHS Foundation Trust, London, UK dUniversity College London Hospitals NHS Foundation Trust, London, UK eSt ...
Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...
This guide explains diabetes insipidus, including common symptoms, hormone causes, diagnosis tests, and medical treatment ...
Pharmacokinetic data from a crossover study demonstrated that the liquid formulation is bioequivalent to an existing FDA-approved oral desmopressin reference product. The Food and Drug Administration ...
The U.S. Food and Drug Administration has approved desmopressin acetate oral solution (Desmoda) for the treatment of central diabetes insipidus in both adults and children, as announced by Eton ...
aDepartment of Endocrinology and Metabolism, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Clinical Center for Diabetes; Shanghai Diabetes ...
The FDA approved desmopressin acetate (Desmoda) oral solution for the management of central diabetes insipidus in adults and children, developer Eton Pharmaceuticals announced. The vasopressin analog ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results